Nasdaq:ADMA
ADMA BIOLOGICS, INC.
A specialized CDMO leader utilizing unique microcarrier technologies to manufacture sterile drug products for global biotech clients.
Key Metrics
Investment Thesis
Bull Case
Investors may favor ADMA due to its transition from a loss-making entity to a profitable one with robust net income of $146.9M and strong gross profit margins on $510.2M in revenue. The company's proprietary technology provides a defensible moat that could capture significant market share as the biologics market expands rapidly. Strong balance sheet with $87.6M in cash allows for strategic acquisitions or further capacity expansion without immediate dilution concerns.
Bear Case
Concerns arise from the large increase in accounts receivable of $108.4M, which may indicate slower collection periods or aggressive revenue recognition practices that could inflate earnings quality. The company's retained earnings deficit of -$161.7M suggests a history of capital consumption that investors must weigh against current profitability. High operating expenses of $101.3M relative to R&D spending of only $4.8M may signal inefficiencies in research utilization or heavy investment in general administration.
About ADMA BIOLOGICS, INC.
ADMA Biologics is a biopharmaceutical contract development and manufacturing organization (CDMO) focused on providing sterile drug products and services to the global biotechnology industry. The company primarily serves markets requiring complex biologics and small-molecule therapies, leveraging its proprietary microcarrier technology to scale production efficiently. Key offerings include large-scale fermentation and purification services critical for bringing new biological therapeutics from lab to patient.
Analysis
Management Discussion
Financial performance has improved significantly with net profit reaching $146.9M in 2025 after recovering from losses in prior years, demonstrating effective cost management and operational scaling. Operating cash flow of $50.4M supports continued R&D investments of $4.8M and capital expenditures of $22.6M without requiring excessive external financing. The substantial increase in accounts receivable to $158.4M reflects growing revenue recognition but warrants monitoring against cash conversion cycles.
Industry Overview
The global contract development and manufacturing organization (CDMO) industry is experiencing rapid growth driven by the increasing complexity of biologics and the outsourcing of manufacturing by pharma giants. Companies like ADMA are positioned to benefit from the shift towards specialized sterile manufacturing, though competition remains fierce on price and service speed. Regulatory scrutiny on supply chain transparency and drug safety continues to be a paramount challenge for all industry participants.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $154.1M | $258.2M | $426.5M | $510.2M |
| Cost of Revenue | $118.8M | $169.3M | $206.9M | $217.4M |
| Gross Profit | $35.3M | $88.9M | $219.6M | $292.8M |
| Operating Expenses | $74.6M | $67.3M | $80.6M | $101.3M |
| Operating Income | $-39.4M | $21.6M | $139.0M | $191.4M |
| R&D | $3.6M | $3.3M | $1.8M | $4.8M |
| G&A | $52.5M | $59.0M | $74.1M | $91.6M |
| Stock-Based Comp | $5.2M | $6.2M | $13.6M | $20.0M |
| D&A | $6.4M | $7.6M | $7.7M | $8.0M |
| Amortization | $715.4K | $724.0K | $388.0K | $144.0K |
| Other OpEx | $18.6M | $5.0M | $4.6M | $5.0M |
| Non-Operating Income | $0 | $0 | $-13.3M | $-8.8M |
| Interest Expense | $19.3M | $25.0M | — | — |
| Interest Income | $44.8K | $1.6M | $2.1M | $1.9M |
| Pre-Tax Income | $-39.4M | $21.6M | $125.7M | $182.7M |
| Income Tax | $0 | $0 | $-72.0M | $35.7M |
| Continuing Ops | $-39.4M | $21.6M | $197.7M | $146.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-65.9M | $-28.2M | $197.7M | $146.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-65.9M | $-28.2M | $197.7M | $146.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $270.4M | $257.0M | $331.4M | $466.5M |
| Cash & Equivalents | $86.5M | $51.4M | $103.1M | $87.6M |
| Accounts Receivable | $15.5M | $27.4M | $50.0M | $158.4M |
| Inventory | $163.3M | $172.9M | $170.2M | $206.5M |
| Prepaid Expenses | $5.1M | $5.3M | $8.0M | $7.5M |
| Other Current Assets | $0 | $0 | $0 | $6.5M |
| Long-Term Assets | $78.1M | $72.2M | $157.3M | $157.7M |
| PP&E (Net) | $58.3M | $53.8M | $54.7M | $65.1M |
| Intangibles | $1.0M | $499.0K | $460.0K | $632.0K |
| Goodwill | $3.5M | $3.5M | $3.5M | $3.5M |
| Operating Leases | $10.5M | $9.6M | $8.6M | $6.7M |
| Other LT Assets | $4.8M | $4.7M | $89.9M | $81.9M |
| Total Assets | $348.5M | $329.2M | $488.7M | $624.2M |
| Current Liabilities | $39.3M | $49.8M | $55.5M | $69.5M |
| Accounts Payable | $13.2M | $15.7M | $20.2M | $22.5M |
| Current Debt | — | — | — | $2.8M |
| Current Leases | $905.4K | $1.0M | $1.2M | $1.1M |
| Deferred Revenue | $142.8K | $182.0K | $143.0K | — |
| Other Current Liab | $25.0M | $32.9M | $34.0M | $43.1M |
| Long-Term Liabilities | $157.2M | $144.2M | $84.1M | $77.4M |
| Long-Term Debt | — | — | — | $69.3M |
| LT Operating Leases | $10.7M | $9.8M | $8.6M | $6.6M |
| Other LT Liab | $146.5M | $134.4M | $75.6M | $1.4M |
| Total Liabilities | $196.5M | $194.0M | $139.7M | $146.9M |
| Shareholders' Equity | $152.0M | $135.2M | $349.0M | $477.3M |
| Paid-In Capital | $630.0M | $641.4M | $657.6M | $671.0M |
| Retained Earnings | $-478.0M | $-506.3M | $-308.6M | $-161.7M |
| Treasury Stock | — | — | — | $32.1M |
| Total L&E | $348.5M | $329.2M | $488.7M | $624.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-65.9M | $-28.2M | $197.7M | $146.9M |
| Non-Cash Adjustments | $-27.7M | $4.7M | $-189.9M | $-238.7M |
| Working Capital Changes | $34.1M | $32.4M | $110.9M | $142.2M |
| Cash from Operations | $-59.5M | $8.8M | $118.7M | $50.4M |
| Capital Expenditures | $13.9M | $4.8M | $8.2M | $22.6M |
| Cash from Investing | $-13.9M | $-5.0M | $-8.6M | $-21.9M |
| Share Buybacks | — | — | — | $31.9M |
| Cash from Financing | $108.9M | $-39.0M | $-58.3M | $-44.0M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $35.4M | $-35.2M | $51.8M | $-15.5M |
| Beginning Cash | $51.1M | $86.5M | $51.4M | $103.1M |
| Ending Cash | $86.5M | $51.4M | $103.1M | $87.6M |
Frequently Asked Questions
How does ADMA BIOLOGICS, INC. make money?
Revenue is driven by contract manufacturing services, specifically sterile drug product manufacturing which accounts for the majority of the $510.2M revenue, alongside related purification and formulation services. The company operates through a global footprint serving both large pharmaceutical companies and emerging biotechnology firms with high-growth potential portfolios.
What are the main risks for ADMA?
The biotechnology sector is inherently capital-intensive and subject to high failure rates in clinical trials, which could lead to client attrition or delayed payments. Regulatory changes in sterile manufacturing standards or intellectual property challenges regarding microcarrier technology could impact operational margins. Concentration risk exists as reliance on a specific niche of sterile drug product manufacturing makes the company sensitive to shifts in demand from this specific therapeutic area.
What is ADMA's competitive advantage?
ADMA possesses proprietary microcarrier-based fermentation technology that offers superior scalability and yield for biologics compared to traditional cell culture methods. The company benefits from a streamlined single-facility approach in certain operations, reducing contamination risks and lowering unit costs for clients. Strong relationships with major biotech sponsors are reinforced by the ability to rapidly scale production capacity as new drug candidates enter clinical trials or commercialization.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.